ReviewAnnals of hematology2020
Clozapine-induced agranulocytosis.
Review in Annals of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 8 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Immune System Alterations in Treatment-Resistant Schizophrenia: A Systematic Review of the Current Evidence and Future Directions.International journal of molecular sciences · 2026Pooled it
- Meta-analyses of clozapine, norclozapine levels and their ratio across three genome wide association studies.Translational psychiatry · 2025Pooled it
- The effectiveness of non-pharmacological treatments for auditory verbal hallucinations in schizophrenia spectrum disorders: A systematic review and meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists · 2025Pooled it
- Saliva Based Clozapine Therapeutic Drug Monitoring: A Systematic Review.Pharmacology research & perspectives · 2025Pooled it
- Clozapine and Pneumonia: Synthesizing the Link by Reviewing Existing Reports-A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Safety of metamizole (dipyrone) for the treatment of mild to moderate pain-an overview of systematic reviews.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review.CNS drugs · 2024Pooled it
- A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.CNS drugs · 2022Guideline
- Association between initial 30-day cumulative clozapine dose and risk of agranulocytosis: A nationwide register-based cohort study.Psychiatry and clinical neurosciences · 2026Article
- Causes of death and mortality patterns in clozapine-treated patients: 17-year retrospective cohort study.BJPsych open · 2026Article
- Clozapine acts as an antagonist of human dopamine DNaunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Xanomeline-Trospium Validates Muscarinic Agonism as an Effective Non-Dopaminergic Treatment for Schizophrenia.International journal of molecular sciences · 2026Review
- Clozapine disrupts the gut-lung microbiota axis, linking gastrointestinal hypomotility to increased respiratory vulnerability.Translational psychiatry · 2026Article
- Analysis of drug-drug interactions between psychiatric drugs in spontaneous adverse drug reaction reports from EudraVigilance.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Genetic Variations in the Dopaminergic Signaling Pathways and Their Implications for Antipsychotics Pharmacogenetics.Journal of molecular neuroscience : MN · 2026Review
- Investigating the relationship between Toll-like receptor activity, low-grade inflammation, cognitive deficits, and antipsychotic drug dose in schizophrenia patients: a moderation analysis.Psychological medicine · 2026Article
- Management of Parkinson's disease psychosis-a European perspective.The Lancet regional health. Europe · 2026Review
- Enhancing Safety Evaluations: A Comprehensive Framework for Evidence-Based Safety Assessment Using the Bradford Hill Criteria.Therapeutic innovation & regulatory science · 2026Article
- Successful Clozapine Rechallenge in a 40-Year-Old Male Patient With Paranoid Schizophrenia After Clozapine-Associated Myocarditis.Case reports in psychiatry · 2026Article
- Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system.Therapeutic advances in psychopharmacology · 2026Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wider use of clozapine, one of the most effective antipshychotic drugs, is precluded by its propensity to cause agranulocytosis. Currently, clozapine is used for treatment-resistant schizophrenia, with mandatory blood count monitoring for the duration of treatment. Agranulocytosis occurs in up to 0.8% of patients and presents a significant medical challenge, despite decreasing mortality rates. In this paper, we review the epidemiology of clozapine-induced agranulocytosis (CLIA), advances in identifying genetic risk factors, and the preventive measures to reduce the risk of CLIA. We discuss the pathogenesis of CLIA, which, despite receiving considerable scientific attention, has not been fully elucidated. Finally, we address the clinical management and suggest the approach to clozapine re-challenge in patients with a previous episode of neutropenia. With a significant proportion of clozapine recipients in Western hemisphere being Black, we comment on the importance of recognizing benign ethnic neutropenia as a potential impediment to clozapine administration. This review aims to aid haematologists and psychiatrists to jointly manage neutropenia and agranulocytosis caused by clozapine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.